NICE is recommending that Norgine's new hepatic encephalopathy drug Targaxan should be funded by the NHS in England in final draft guidance.

The drug-pricing watchdog is recommending that Norgine's Targaxan (rifaximin) be funded as a treatment option for preventing recurrent episodes of hepatic encephalopathy, a brain condition caused by liver failure.

The disorder causes patients to become confused, lose consciousness or, in more serious cases, fall into a coma, as a result of problems with their liver. It affects around 10,000 people in the UK.

For more details, go to: http://www.pmlive.com/pharma_news/norgine_close_to_final_yes_from_nice_on_targaxan_655749